Levin Frances Rudnick, McDowell David, Evans Suzette M, Nunes Edward, Akerele Evaristo, Donovan Stephen, Vosburg Suzanne K
Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 66, New York, NY 10032, USA.
Am J Addict. 2004 Jan-Feb;13(1):21-32. doi: 10.1080/10550490490265280.
There is a noticeable lack of targeted treatment options for marijuana dependence, in particular pharmacologic approaches. This is the first study evaluating a targeted pharmacologic approach for marijuana dependence. The goals of the study were to determine if such patients would seek pharmacologic treatment, whether these patients could be retained in treatment using a design previously developed for cocaine-dependent patients, and especially whether divalproex sodium showed promise as a treatment agent for marijuana dependence. We found that marijuana-dependent patients will seek treatment, and such patients can be adequately maintained in a pharmacologic trial. Regardless of treatment group, patients reported a significant reduction in their frequency and amount of marijuana use as well as a reduction in irritability. Given the lack of proven effective treatments for marijuana dependence, pharmacotherapies should be sought. The design of a preliminary clinical trial should include a psychosocial/behavioral intervention emphasizing motivation and medication compliance and a placebo control group.
对于大麻依赖，尤其是药物治疗方法，明显缺乏有针对性的治疗选择。这是第一项评估针对大麻依赖的靶向药物治疗方法的研究。该研究的目的是确定此类患者是否会寻求药物治疗，这些患者能否使用先前为可卡因依赖患者开发的设计方案继续接受治疗，特别是丙戊酸钠是否显示出作为大麻依赖治疗药物的前景。我们发现，大麻依赖患者会寻求治疗，并且此类患者可以在药物试验中得到充分维持。无论治疗组如何，患者报告其大麻使用频率和使用量均显著减少，易怒情绪也有所减轻。鉴于缺乏经证实有效的大麻依赖治疗方法，应寻求药物治疗。初步临床试验的设计应包括强调动机和药物依从性的心理社会/行为干预以及安慰剂对照组。
